| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Chengdu huasun technology group Inc. , LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.69 |
| 52 Week High | CN¥5.87 |
| 52 Week Low | CN¥3.02 |
| Beta | 0.21 |
| 1 Month Change | -9.34% |
| 3 Month Change | -19.61% |
| 1 Year Change | -18.18% |
| 3 Year Change | -36.71% |
| 5 Year Change | -30.02% |
| Change since IPO | -44.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 790 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.7% | 0.8% | -0.4% |
| 1Y | -18.2% | -13.4% | -14.4% |
Return vs Industry: 000790 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 000790 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
| 790 volatility | |
|---|---|
| 790 Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 000790's share price has been volatile over the past 3 months.
Volatility Over Time: 000790's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 899 | Mingliang Huang | www.huasungrp.com |
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs.
Chengdu huasun technology group Inc. , LTD. Fundamentals Summary
| 790 fundamental statistics | |
|---|---|
| Market cap | CN¥2.32b |
| Earnings (TTM) | CN¥36.37m |
| Revenue (TTM) | CN¥938.87m |
63.7x
P/E Ratio2.5x
P/S RatioIs 790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 790 income statement (TTM) | |
|---|---|
| Revenue | CN¥938.87m |
| Cost of Revenue | CN¥589.40m |
| Gross Profit | CN¥349.47m |
| Other Expenses | CN¥313.10m |
| Earnings | CN¥36.37m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.058 |
| Gross Margin | 37.22% |
| Net Profit Margin | 3.87% |
| Debt/Equity Ratio | 24.5% |
How did 790 perform over the long term?
See historical performance and comparison